原发性肝癌切除术后预防性经肝动脉介入治疗：肝动脉化疗栓塞术和化疗灌注术比较

摘要

Objective To compare the therapeutic efficacy of preventive transcatheter arterial chemoembolization (TACE) with that of preventive transhepatic arterial infusion (TAI) for patients with primary hepatocellular carcinoma (HCC) after hepatectomy. Methods During the period from June 2011 to June 2012 at authors’ hospital, preventive transhepatic interventional therapy was employed in 79 HCC patients within three months after hepatectomy. The followed-up endpoint was in June 2013. The clinical data were retrospectively analyzed. The patients were divided into TACE group (n=41) and TAI group (n=38). No significant differences in age, sex, preoperative liver function, Child-Pugh scores, tumor size and AFP level existed between the two groups. During interventional procedure , catheterization of proper hepatic artery was performed first, which was followed by angiography in order to clarify that there were no newly-developed tumor vessels or tumor lesions in the residual liver, then the chemotherapeutic agents were infused through the catheter. The emulsion of iodized oil with chemotherapeutic agent was used in the patients of TACE group, while only chemotherapeutic agent was adopted in the patients of TAI group. By using Chi-square test the one-year recurrence rate was determined. Kaplan-Meier estimation method was used to calculate the disease-free survival time, and t test was adopted to estimate the mean hospitalization days. The results were compared between the two groups. Results Of the 79 patients, postoperative recurrence was confirmed in 11, and the overall one-year recurrence rate was 13.9%. The one-year recurrence rate of TACE group and TAI group was 12.20% and 15.79% respectively , and no significant difference in one- year recurrence rate existed between TACE group and TAI group (χ2= 0.213, P = 0.645). The average disease-free survival time of TACE group and TAI group was (21.60 ± 1.52) months and (17.38 ± 3.01) months respectively, the difference between the two groups was of statistical significance (P = 0.038). The mean hospitalization days of TACE group and TAI group were (6.30 ± 1.84) days and (5.89 ± 2.08) days respectively, and the difference between the two groups was not statistically significant (P = 0.522). Conclusion No significant difference in one-year recurrence rate exists between the patients receiving preventive TACE and the patients receiving preventive TAI after hepatectomy for HCC. Nevertheless , preventive TACE can probably improve the disease-free survival time after hepatectomy.%目的：探讨原发性肝癌切除术后行预防性经肝动脉化疗栓塞术（TACE）或化疗灌注术（TAI）的疗效比较。方法回顾性分析2011年6月-2012年6月行原发性肝癌切除术并在术后1~3个月行预防性介入治疗的79例患者，研究终点为2013年6月。病例分为TACE（n=41）和TAI（n=38）2组。2组患者术前年龄、性别、肝功能Child-Pugh评分、术前肿瘤直径及AFP水平差异均无统计学意义。介入术中将导管超选进入肝固有动脉，造影证实无新生肿瘤血管和肿瘤病灶后经导管注入药物，TACE组采用碘油化疗药物乳剂，TAI 组则采用单纯化疗药物灌注。采用卡方检验比较2组的1年复发率， Kaplan-Meier 估计法比较无瘤生存期，t检验比较平均住院日差别。结果79例患者中共有11例患者确认为切除术后复发，总体1年复发率为13．9%，其中TACE组1年复发率为12．2%（5/41），TAI组为15．8%（6/38），差异无统计学意义（χ2=0．213，P=0．645）。 TACE组平均无瘤生存期为（21．6±1．5）个月，TAI组为（17．4±3．0）个月，TACE组明显优于TAI组（P =0．038）。 TACE组平均住院日为（6．3±1．8）d，TAI组为（5．9±2．1）d，两组差异无统计学意义（P=0．522）。结论原发性肝癌切除术后行预防性TACE或TAI的1年复发率无差别，但采用TACE可望提高患者术后的无瘤生存期。